A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Condition: Urothelial Cancer · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (345)
| Alaska Urological Institute dba Alaska Clinical Research Center | Anchorage, Alaska, United States | — |
| University of Calif Davis Medical Center | Sacramento, California, United States | — |
| St. Helena Hospital - Martin-O'Neil Cancer Center | St. Helena, California, United States | — |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| University of Miami Sylvester Cancer Center | Miami, Florida, United States | — |
| Mid Florida Hematology Oncology | Orange, Florida, United States | — |
| Piedmont Cancer Institute | Atlanta, Georgia, United States | — |
| Rush University | Chicago, Illinois, United States | — |
| Edward Hines Jr V A Hospital | Hines, Illinois, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
| Maryland Oncology Hematology, PA | Lanham, Maryland, United States | — |
| University of Michigan Health System | Ann Arbor, Michigan, United States | — |
+ 333 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03390504